Note 17 - Segments and Geographical Information (Tables)

12 Months Ended

Dec. 31, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

Year Ended December 31, 2025
	Regenerative Biotech			Consumer Health Products		Consolidated Total
Revenue
Product revenue	$	—		$	704	$	704
Significant Expense Categories (provided to CODM)
Cost of sales		—			646		646
Research and development		2,653			—		2,653
Sales and marketing		23			44		67
General and administrative (a)		4,238			15		4,253
Total significant segment expenses		6,914			705		7,619
Other Segment Items
Other segment items (b)		45			1		46
Segment net loss	$	(6,869	)	$	—	$	(6,869	)

Year Ended December 31, 2024
	Regenerative Biotech			Consumer Health Products			Consolidated Total
Revenue
Product revenue	$	—		$	430		$	430
Significant Expense Categories (provided to CODM)
Cost of sales		—			270			270
Research and development		2,310			—			2,310
Sales and marketing		4			550			554
General and administrative (a)		4,927			95			5,022
Total significant segment expenses		7,241			915			8,156
Other Segment Items
Other segment items (b)		(6	)		—			(6	)
Segment net loss	$	(7,247	)	$	(485	)	$	(7,732	)

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

	December 31,
	2025		2024
Cash and cash equivalents:
Regenerative Biotech	$	1,206	$	2,405
Consumer Health Products		146		81
Total	$	1,352	$	2,486
Total assets:
Regenerative Biotech	$	2,277	$	3,978
Consumer Health Products		400		464
Total	$	2,677	$	4,442